PL EN


Preferences help
enabled [disable] Abstract
Number of results
2012 | 10 | 2 | 141-149
Article title

Rak szyjki macicy – czy zawsze chirurgia?

Content
Title variants
EN
Cervical cancer – does it always require surgery?
Languages of publication
EN
Abstracts
EN
Worldwide, cervical cancer is the second most common genital malignancy in the females. Estimated number of women affected therewith reaches 1.4 million. In Poland, cervical cancer is the fourth most common cancer, preceded by breast cancer, lung cancer and endometrial cancer, and the fifth most common cause of cancer-related mortality. Cervical cancer usually affects women aged 45-59. Current standards of treatment of cervical cancer include surgery (still the basic modality at stages 0, IA, IB and IIA), radiotherapy, chemotherapy and radiochemotherapy, which are implemented at stages IB-IVB. Surgical treatment of cervical cancer patients is classified as follows: primary treatment, treatment of coexisting genital conditions prior to planned radiochemotherapy, treatment of recurrent cervical cancer and palliative treatment. Low efficacy of radiotherapy and chemotherapy as the sole treatment modalities in cervical cancer resulted in increased interest in radiochemotherapy, i.e. a technique combining radiation with cytotoxic drugs. Randomized trials revealed an improvement of 3-years’ survival by 10-18% and the drug used most often was cisplatin administered alone or combined with a 96-hours’ infusion of fluorouracil. Cervical cancer is currently considered one of the tumors, where multimodal treatment is a therapeutic standard.
PL
W skali świata rak szyjki macicy jest drugim co do częstości występowania nowotworem narządów płciowych u kobiet. Szacuje się, że liczba kobiet chorych na raka szyjki macicy na świecie sięga 1,4 miliona. W Polsce rak szyjki macicy zajmuje czwarte miejsce – po raku sutka, płuc i endometrium – oraz piąte miejsce jako przyczyna zgonów wśród kobiet z powodu nowotworów złośliwych. Rak szyjki macicy najczęściej rozwija się u kobiet pomiędzy 45. a 59. rokiem życia. Współczesne standardy leczenia raka szyjki macicy obejmują: leczenie chirurgiczne, które wciąż jest podstawą w stopniu 0, IA, IB, IIA, radioterapię, chemioterapię oraz radiochemioterapię, które stosuje się w stopniach od IB do IVB. Leczenie chirurgiczne u chorych z rakiem szyjki macicy dzieli się na następujące typy: leczenie pierwotne, leczenie współistniejących patologii narządów płciowych przed planowaną radiochemioterapią, leczenie nawrotów raka szyjki macicy i leczenie paliatywne. Niska skuteczność radioterapii i chemioterapii stosowanych samodzielnie w raku szyjki macicy spowodowała wzrost zainteresowania radiochemioterapią, czyli metodą łączącą leczenie promieniami i lekami cytotoksycznymi. W badaniach randomizowanych stwierdzono poprawę 3-letniego przeżycia o 10-18%, a lekiem najczęściej stosowanym jest cisplatyna podawana oddzielnie lub w skojarzeniu z 96-godzinnym wlewem fluorouracylu. Rak szyjki macicy należy obecnie do nowotworów, w których leczenie skojarzone stanowi standard terapeutyczny.
Discipline
Year
Volume
10
Issue
2
Pages
141-149
Physical description
References
  • 1. Ferlay J., Bray F., Pisani P., Parkin D.M.: GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. IARCPress, Lyon 2004.
  • 2. Krajowa Baza Danych Nowotworowych. Zakład Epidemiologii i Prewencji Nowotworów, Centrum Onkologii – Instytut w Warszawie. Adres: www.onkologia.org.pl.
  • 3. Berrino F., De Angelis R., Sant M. i wsp.; EUROCARE Working group: Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol. 2007; 8: 773-783.
  • 4. Kornafel J., Izmajłowicz B.: Radiochemioterapia raka szyjki macicy. W: Spaczyński M., Kędzia W., Nowak-Markwitz E. (red.): Rak szyjki macicy. Profilaktyka, diagnostyka i leczenie. PZWL, Warszawa 2009: 299-306.
  • 5. Bidziński M., Dańska-Bidzińska A.: Leczenie chirurgiczne stanów przedrakowych i raka szyjki macicy. W: Spaczyński M., Kędzia W., Nowak-Markwitz E. (red.): Rak szyjki macicy. Profilaktyka, diagnostyka i leczenie. PZWL, Warszawa 2009: 287-297.
  • 6. Anderson F.F.: Treatment and follow up of noninvasive cancer of the uterine cervix: report of 205 cases (1948-57). J. Obstet. Gynecol. Br. Commonw. 1965; 72: 172-177.
  • 7. Kolstad P., Klem V.: Long-term followup of 1121 cases of carcinoma in situ. Obstet. Gynecol. 1976; 48: 125-129.
  • 8. Kennedy A.W., Belinson J.L., Wirth S., Taylor J.: The role of the loop electrosurgical excision procedure in the diagnosis and management of early invasive cervical cancer. Int. J. Gynecol. Cancer 1995; 5: 117-120.
  • 9. Suwannarurk K., Bhamarapravati S., Thaweekul Y. i wsp.: The accuracy of cervical cancer and cervical intraepithelial neoplasia diagnosis with loop electrosurgical excisional procedure under colposcopic vision. J. Gynecol. Oncol. 2009; 20: 35-38.
  • 10. Miroshnichenko G.G., Parva M., Holtz D.O. i wsp.: Interpretability of excisional biopsies of the cervix: cone biopsy and loop excision. J. Low. Genit. Tract Dis. 2009; 13: 10-12.
  • 11. Hacker N.F.: Cervical cancer. W: Berek J.S., Hacker N.F. (red.): Practical Gynecologic Oncology. Lippincott Williams & Wilkins, Philadelphia 2005.
  • 12. Maneo A., Landoni F., Cormio G. i wsp.: Radical hysterectomy for recurrent or persistent cervical cancer following radiation therapy. Int. J. Gynecol. Cancer 1999; 9: 295-301.
  • 13. Rutledge S., Carey M.S., Prichard H. i wsp.: Conservative surgery for recurrent or persistent carcinoma of the cervix following irradiation: is exenteration always necessary? Gynecol. Oncol. 1994; 52: 353-359.
  • 14. Höckel M.: Laterally extended endopelvic resection. Novel surgical treatment of locally recurrent cervical carcinoma involving the pelvic side wall. Gynecol. Oncol. 2003; 91: 369-377.
  • 15. 1Caceres A., Chi D.S., Boland P.J. i wsp.: Superior pubic rami resection for isolated recurrent uterine cancer. Gynecol. Oncol. 2007; 104 (supl. 1): 45-47.
  • 16. Girinski T., Pejovic-Lenfant M.H., Bourhis J. i wsp.: Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int. J. Radiat. Oncol. Biol. Phys. 1989; 16: 37-42.
  • 17. Urbański K., Klimek M., Bieda T. i wsp.: Leczenie skojarzone chorych na raka szyjki macicy. Współcz. Onkol. 2006; 6: 280-284.
  • 18. Bookman M.A., Blessing J.A., Hanjani P. i wsp.: Topotecan in squamous cell carcinoma of the cervix: a Phase II study of the Gynecologic Oncology Group. Gynecol. Oncol. 2000; 77: 446-449.
  • 19. Burnett A.F., Roman L.D., Garcia A.A. i wsp.: A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix. Gynecol. Oncol. 2000; 76: 63-66.
  • 20. Chaney A.W., Eifel P.J., Logsdon M.D. i wsp.: Mature results of a pilot study of pelvic radiotherapy with concurrent continuous infusion intra-arterial 5-FU for stage IIIB-IVA squamous cell carcinoma of the cervix. Int. J. Radiat. Oncol. Biol. Phys. 1999; 45: 113-118.
  • 21. Lowrey G.C., Mendenhall W.M., Million R.R.: Stage IB or IIA-B carcinoma of the intact uterine cervix treated with irradiation: a multivariate analysis. Int. J. Radiat. Oncol. Biol. Phys. 1992; 24: 205-210.
  • 22. Mundt A.J., Lujan A.E., Rotmensch J. i wsp.: Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 2002; 52: 1330-1337.
  • 23. Souhami L., Gil R.A., Allan S.E. i wsp.: A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J. Clin. Oncol. 1991; 9: 970-977.
  • 24. Sardi J., Sananes C., Giaroli A. i wsp.: Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Gynecol. Oncol. 1990; 38: 486-493.
  • 25. Peters W.A. 3rd, Liu P.Y., Barrett R.J. 2nd i wsp.: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 2000; 18: 1606-1613.
  • 26. Keys H.M., Bundy B.N., Stehman F.B. i wsp.: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Engl. J. Med. 1999; 340: 1154-1161.
  • 27. Whitney C.W., Sause W., Bundy B.N. i wsp.: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J. Clin. Oncol. 1999; 17: 1339-1348.
  • 28. Rose P.G., Bundy B.N., Watkins E.B. i wsp.: Concurrent cisplatin- based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 1999; 340: 1144-1153.
  • 29. Morris M., Eifel P.J., Lu J. i wsp.: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N. Engl. J. Med. 1999; 340: 1137-1143.
  • 30. Rose P.G., Blessing J.A., Gershenson D.M., McGehee R.: Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 1999; 17: 2676-2680.
  • 31. Pearcey R., Brundage M., Drouin P. i wsp.: Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J. Clin. Oncol. 2002; 20: 966-972.
  • 32. Loizzi V., Cormio G., Loverro G. i wsp.: Chemoradiation: a new approach for the treatment of cervical cancer. Int. J. Gynecol. Cancer 2003; 13: 580-586.
  • 33. Obermair A., Cheuk R., Horwood K. i wsp.: Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: preliminary results. Cancer 2001; 92: 903-908.
  • 34. Torbé B.: [Estimation of treatment results and side-effects in patients with invasive uterine cervix cancer stage IIB-IVA treated with concurrent radiochemotherapy]. Ann. Acad. Med. Stetin. 2008; 54: 28-40.
  • 35. Torbé B., Falco M., Torbé A. i wsp.: Radiotherapy versus radiochemotherapy with cisplatin in treatment of cervical cancer. Med. Oncol. 2010; 27: 1-8.
  • 36. Abu-Rustum N.R., Lee S., Correa A., Massad L.S.: Compliance with and acute hematologic toxic effects of chemoradiation in indigent women with cervical cancer. Gynecol. Oncol. 2001; 81: 88-91.
  • 37. Higgins R.V., Naumann W.R., Hall J.B., Haake M.: Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. Gynecol. Oncol. 2003; 89: 499-503.
  • 38. Vrdoljak E., Hamm W.: Current state-of-the-art of concomitant chemoradiation in cervical carcinomas. Eur. J. Gynaecol. Oncol. 2003; 24: 475-479.
  • 39. Pinheiro W., Pereira A.K., Soares J.M. Jr, Baracat E.C.: Is the combination of mitomycin C, bleomycin and methotrexate effective as a neoadjuvant treatment for cervical cancer in women? Eur. J. Gynaecol. Oncol. 2011; 32: 37-39.
  • 40. Eifel P.J.: Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer. Nat. Clin. Pract. Oncol. 2006; 3: 248-255.
  • 41. Pérez-Regadera J., Sánchez-Muñoz A., De-la-Cruz J. i wsp.: Cisplatin-based radiochemotherapy improves the negative prognosis of c-erbB-2 overexpressing advanced cervical cancer. Int. J. Gynecol. Cancer 2010; 20: 164-172.
  • 42. Nagy V., Coza O., Ordeanu C. i wsp.: Radiotherapy versus concurrent 5-day cisplatin and radiotherapy in locally advanced cervical carcinoma. Long-term results of a phase III randomized trial. Strahlenther. Onkol. 2009; 185: 177-183.
  • 43. Kahmann L., Beyer U., Mehlhorn G. i wsp.: Mitomycin C in patients with gynecological malignancies. Onkologie 2010; 33: 547-557.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-1ddcd148-8678-437b-a8b9-d1baf83f4c5b
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.